Margaret McGlynn
Director
Corporate Governance and Nominating Committee, Chair
Science and Technology Committee, Member
Ms. McGlynn joined our board in 2011. Ms. McGlynn retired from Merck & Co. in 2009, where she served as President, Vaccines and Infectious Diseases, and as President, Hospital and Specialty Products. During her 26-year career at Merck, she also held various leadership roles in the U.S. and globally in marketing, sales, managed care and business development. Following her retirement, Ms. McGlynn served as the President and Chief Executive Officer of the International AIDS Vaccine Initiative, a global not-for-profit organization whose mission is to ensure the development of safe, effective and accessible HIV vaccines for use throughout the world, from 2011 until 2015. Ms. McGlynn served as a member of the board of directors for Air Products and Chemicals, Inc., a company specializing in gases and chemicals for industrial uses, from 2005 to November 2020. Ms. McGlynn serves as a member of the board of directors for Amicus Therapeutics, Inc., a biopharmaceutical company, as well as a member of the board of directors for Novavax, Inc., a late-stage biotechnology company. She is also a member of the National Industrial Advisory Committee at the University at Buffalo School of Pharmacy and Pharmaceutical Sciences. Ms. McGlynn holds a B.S. in pharmacy, an M.B.A. in marketing and an Honorary Doctorate from the State University of New York at Buffalo.
Ms. McGlynn joined our board in 2011. Ms. McGlynn retired from Merck & Co. in 2009, where she served as President, Vaccines and Infectious Diseases, and as President, Hospital and Specialty Products. During her 26-year career at Merck, she also held various leadership roles in the U.S. and globally in marketing, sales, managed care and business development. Following her retirement, Ms. McGlynn served as the President and Chief Executive Officer of the International AIDS Vaccine Initiative, a global not-for-profit organization whose mission is to ensure the development of safe, effective and accessible HIV vaccines for use throughout the world, from 2011 until 2015. Ms. McGlynn served as a member of the board of directors for Air Products and Chemicals, Inc., a company specializing in gases and chemicals for industrial uses, from 2005 to November 2020. Ms. McGlynn serves as a member of the board of directors for Amicus Therapeutics, Inc., a biopharmaceutical company, as well as a member of the board of directors for Novavax, Inc., a late-stage biotechnology company. She is also a member of the National Industrial Advisory Committee at the University at Buffalo School of Pharmacy and Pharmaceutical Sciences. Ms. McGlynn holds a B.S. in pharmacy, an M.B.A. in marketing and an Honorary Doctorate from the State University of New York at Buffalo.